The SFRP1, SFRP2, SFRP3, and SFRP4 levels in the AD patients with or without end-point events were increased compared with the NAD group, while the SFRP5 levels were reduced (Figures 2A–E). Here, SFRP4 is linked to Alzheimer disease.